基于3D打印的拉波尼特/阿尔金酸水凝的假药,用于多用途的药物加载和释放
Elena Munoz-Perez1,2, J Rubio-Retama3, Lorena Cussó4,5,6
1NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006, Vitoria Gasteiz, Spain.
Drug delivery and translational research
|January 7, 2024
概括
这项研究引入了使用拉波尼特-酸水凝的新型3D打印支架 (3DPS). 一种新的印刷后药物加载方法提高了多功能性和释放性,在直肠治疗中显示出有希望的体内结果.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
背景情况:
- 传统的假药面临着局限性,阻碍了直肠治疗的进展.
- 增材制造提供了创新的制造,但缺乏材料进步.
- 现有的3D打印体 (3DPS) 方法经常使用常规车辆,限制了开发.
研究的目的:
- 开发一种基于拉波尼特-酸水凝的新型3D打印体 (3DPS).
- 为3DPS引入一个新的印刷后药物加载策略.
- 为了增强3DPS的药物释放和分解特性.
主要方法:
- 使用拉波尼特-酸盐水凝油墨制造3DPS.
- 开发各种分子模型的被动后打印药物加载策略.
- 实施一个取代策略来修改拉波尼特矩阵以改善药物释放.
- 在老鼠模型中对3DPS的体内评估.
主要成果:
- 成功制造了基于拉波尼特-酸水凝的3DPS.
- 对于不同电荷和大小的分子,印刷后装载的多功能性已被证明.
- 通过矩阵移位实现3DPS的增强药物扩散和快速分解.
- 在老鼠体内观察到积极的行为,具有非阻塞性特征和正常的肠移动性.
结论:
- 基于拉波尼特-酸水凝的新型3DPS与印刷后药物加载提供了一个多功能和高效的平台,用于直肠药物输送.
- 开发的策略显著改善了药物释放和片分解.
- 3DPS在体内表现出适当的性能,为先进的直肠疗法铺平了道路.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


